Stock comparison
Haemonetics
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 72B | LLY |
| Benjamin Graham | 85A | 86A | LLY |
| Philip Fisher | 60C | 86A | LLY |
| Peter Lynch | 54C | 74B | LLY |
| Joel Greenblatt | 31F | 78C | LLY |
| Charlie Munger | 54D | 85A | LLY |
| Terry Smith | 55D | 77C | LLY |
Side-by-side metrics
| Metric | HAE | LLY |
|---|---|---|
| Market cap | $2.98B | $1T |
| P/E (TTM) | 24.8x | 36.6x |
| EV/EBIT | 14.1x | 34.1x |
| ROIC (TTM) | 8.37% | 32.06% |
| Gross margin | 55.74% | 83.51% |
| Net margin | 7.29% | 34.98% |
| Revenue CAGR 5y | 7.65% | 23.17% |
| EPS CAGR 5y | 24.62% | 40.81% |
| Debt / Equity | 1.5x | 1.4x |
| Dividend yield | 0.0% | 0.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EV/EBIT14.1xvs 34.1x+59%
- P/E (TTM)24.8xvs 36.6x+32%
LLY leads on
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $2.98B+100%
- Net margin34.98%vs 7.29%+79%
- ROIC (TTM)32.06%vs 8.37%+74%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.